Photo by nci from unsplash
The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the… Click to show full abstract
The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing.
Keywords:
subcutaneous turoctocog;
preliminary efficacy;
efficacy subcutaneous;
immunogenicity safety;
safety preliminary;
pharmacokinetics immunogenicity
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!